In Review: The Connecticut legislature gaveled in this week to kick off the 2026 Legislative Session. This year’s session is a short one and adjourns on May 6. If you have any questions, please contact Sam Hallemeier at shallemeier@pcmanet.org.
In Review: PCMA met with Connecticut’s Taft-Hartley Trust to discuss the bills dealing with delinking, fiduciary, and a ban on spread pricing. The Taft-Hartley helped defeat a prior authorization bill last year. We focused the discussion on how these bills
In Review: PCMA testified in the Human Services Committee on SB 11 and HB 7192. Both bills result from the Rx Drug Task Force, which met over the past few months. Both bills include delinking, fiduciary to the health plan
In Review: PCMA met with House leadership and members of the Insurance and Real Estate Committee to discuss the legislative proposals the Senate Democrats are pushing. Those proposals include “delinking”, PBMs acting as fiduciaries, and a ban on spread pricing.
In Review: Senate Bill 1366 was introduced and scheduled for a hearing in the Insurance and Real Estate Committee on Thursday, February 27,at 10:00 A.M. The bill includes “delinking”, a fiduciary duty to the health plan, patients, and pharmacies, and
In Review: PCMA met with Senate Chair Matt Lesser (D) of the Human Services Committee to discuss the Rx Drug Task Force. The Senator had questions about how PBMs are compensated for their services, pharmacy reimbursements, and PBMs as fiduciaries.
In Review: PCMA participated in the Prescription Drug Task Force’s PBM Oversight Subcommittee where the Office of Health Strategy gave a presentation on the PBM report they will release late this month. Senator Saud Anwar (D), Senate Chair of the
In Review: PCMA attended the Prescription Drug Task Force press event and kick-off meeting, where the legislature and healthcare community members will discuss the rising costs of medications and address challenges in prescription drug access across Connecticut. Four subcommittees will meet virtually
In Review: The Office of Health Strategy (OHS) held an informational benchmarking hearing to review their 2021-2022 benchmarking reporting. OHS discussed the retail pharmacy spending trends for the year and was concerned about brand-name drug price increases. OHS invited three
In Review: The Connecticut legislature adjourned early Thursday morning where PCMA successfully defeated a ban on step therapy, requiring the carrier to provide the burden of proving that medication is unnecessary and a prescription drug affordability board with the ability
